Full reports on GRCU, MDNT, GRDO, and QEDN are below Special Situation Alert
Below is a few key points on ALKM with a PDF that provides a full analyst report
The next generation of bottled water is here!
Alkame Holdings, Inc. (OTCQB: ALKM)
Alkame Holdings, Inc. (OTCBB:ALKM), through its wholly owned subsidiary, Alkame Water, Inc. is an innovative technology and health company that distributes bottled water with a patented technology and patented formula that alters the molecular structure of water, producing a combination of characteristics that are unprecedented in the beverage industry. Its patented technology restructures the water, allowing for true-hydration, which improves health and vitality. Health and eco-conscious people of all ages and walks from pro-athletes, actors and artists to everyday people and children reap the benefits of our unique water — down to its 100% recyclable eco-friendly packaging. Alkame holds distributorship rights to market and sell bottled water in the United States, Canada and Mexico.
Actor, Robert Downey Jr.
Robby Gould, Chicago Bears
ALKM Report Written by Michael Anderegg,
Chartered Financial Analyst
Experienced investment professional specializing in financial markets research with significant technical and fundamental competencies. Comprehensive analytical framework incorporates time cycle and multi-timeframe trend analysis to cover a wide variety of instruments and market conditions.
Published June 10, 2014
Use the PDF Icon provided below to get the full report on ALKM.
Research Reports Written by Mark Bonacci,
Chief Financial Analyst
Mark Bonacci has worked on Wall Street for several years in various financial services roles and is a
self-employed investment analyst and equity trader
Published June 10, 2014
Green Cures & Botanical Distribution, Inc. (OTCBB: GRCU) FULL REPORT
Green Cures announced the addition of CBD Capsules to its line of products to debut in the upcoming weeks. Green Cures’ set of 30 CBD Capsules will initially contain 50 milligrams of Pure CBD-Hemp Oil per capsule. Green Cures’ CBD Capsules do not contain controlled substances, as their low THC content falls within federal guidelines. Therefore, Green Cures will be able to market, distribute and sell its upcoming product online and through retailers across the nation. Cannabidiol (CBD) has been the subject of numerous scientific studies at several academic research centers in the United States and across the globe. It is the second most prominent ingredient found in the Cannabis plant, accounting for up to 40% of the plant’s extract. According to published scientific and clinical studies, CBD may act in the form of an experimental model to improve a wide range of conditions, including epilepsy, arthritis, rheumatoid, diabetes, alcoholism, chronic pain, schizophrenia, antibiotic-resistant infections, and other neurological disorders.
Green Cures is exploring additional opportunities to expand its services and operations within the hemp and cannabis industry, particularly, in the field of agriculture. “Currently, in the United States, the demand for high quality raw material throughout the hemp industry and cannabis medicinal field outstrips the supply; therefore, we are exploring the possibility of being able to supply raw materials for our current and upcoming products, domestically and internationally,” said Green Cures CEO Robert Calkin. At the present time, Green Cures plans to form its first subsidiary company, which will operate in the field of agriculture, as permitted by law. Furthermore, Green Cures is reviewing and has been in negotiations with several highly qualified individuals in the fields of horticulture and microbiology, with a view to their potentially joining the new subsidiary in the near future.
Green Cures is also pleased to announce that it has received an exclusive invitation to be part of the “International Cannabis Association” exposition scheduled for June 22, 2014, in Las Vegas, Nevada, where Green Cures will proudly showcase its current and upcoming line of products and services available to the public, as of the date of that event.
Mediant Studios, Inc. (OTCBB: MDNT) FULL REPORT
Medient Studios will release Nick Cassavetes’ Yellow on August 29 in New York, San Francisco, Los Angeles, Seattle and Chicago, followed by a planned expansion nationwide. A festival favorite, Yellow has been screened to great critical acclaim at over a dozen film festivals around the world, including Toronto International Film Festival, Tokyo International Film Festival, Munich Film Festival, Seattle International Film Festival, Sitges Film Festival and SXSW among others. The film also won the “Best Feature Film” award at the Catalina Film Festival in September 2013.
Nick Cassavetes, the director and writer of Yellow, said, “I guess what I’m interested in today is putting up on screen something that is consistent with what I see when I walk out my front door. And granted, I’m a little crazy, but ‘Yellow’ comes pretty darn close.”
A visually dazzling head-trip from director Nick Cassavetes (The Notebook, The Other Woman), Yellow tells the story of Mary Holmes, (Heather Wahlquist), a young substitute teacher who escapes from her drudging everyday life by fantasizing bizarre parallel realities. We enter her hallucinatory world, peopled with Busby Berkeley dancers, Cirque du Soleil, Circus freaks, and human farm animals, where nothing is quite what it seems. Yellow stars Heather Wahlquist, Sienna Miller, Melanie Griffith, Lucy Punch, Gena Rowlands, David Morse, Daveigh Chase, Max Thieriot, Riley Keough, Ethan Suplee, Brendon Sexton and Ray Liotta.
The company has made substantial progress in paying off the debt associated with the production and acquisition of the movie. Most of the film’s investors and related debts have now been paid in full. These include the Screen Actors Guild ($311,000), film investor Pankaj Rajani ($660,000), and Indion Finance, LLC ($600,000). The sole cash loan facility on the film was secured from AMAG, Inc. A total of $812,236 out of a principal of $1,000,000 has been paid to AMAG. The balance of the principal and accrued interest is $551,432. Of this, a sum of $250,000 will be deferred until after the release of the film. The film’s principal services creditor, the Prime Focus Group has been paid $1,125,000 out of the total outstanding invoice of $2,500,000. Prime Focus has also agreed to defer $1,000,000 until after the film has been released. The two other notes on the film — Tommee May ($180,000) and Derreck Lee ($720,000) are not due until after the release of the film. In summary, $3,082,236 has been paid, $676,000 is to be paid prior to release, and the balance of $2,150,000 has been deferred to be paid out of film revenues.
Guard Dog, Inc. (OTCBB: GRDO) FULL REPORT
Guard Dog, Inc. recently appointed Bill Schaefer as President of the Company. Mr. Schaefer brings to the Company a unique combination of both operational business talent coupled with keen knowledge and understanding of the public markets.
Mr. Schaefer, newly appointed President of Guard Dog, Inc., stated, “I am very pleased and extremely excited about the opportunities that lay ahead for the Company.”
Mr. Schaefer further stated, “It is my goal to take the Company and its shareholders into a new and exciting business direction, which will include a new Company name, as well as a new stock symbol with a new Company web site.”
Mr. Schaefer is very mindful of preserving shareholder’s value. With that in mind, he is ensuring that all necessary action is taken to bring the Company to Current status on OTCMarkets as soon as possible. Additionally, he has no plans for a company stock splits for the foreseeable future. Mr. Schaefer looks forward to providing additional insight into corporate strategy with further updates in the near term.
Market Value $928,795 a/o Jun 06, 2014
Shares Outstanding 1,857,589,568 a/o May 30, 2014
Float 1,816,047,996 a/o May 30, 2014
Authorized Shares 6,000,000,000 a/o May 30, 2014
Par Value 0.0001
QED Connect, Inc. (OTCBB: QEDN) FULL REPORT
QED Connect, Inc. has acquired Emerald Med Farms, LLC, a California based medical marijuana company. The company will be a wholly owned subsidiary of QED Connect, Inc.
Emerald Med Farms is a newly launched enterprise that cultivates, harvests cannabis for the medical marijuana industry with a business philosophy to be the “Cannabis Purveyors of the Highest Quality”. They have developed an exceptional methodology of employing a continuous sterile environment during all stages of operations to ensure that the product maintains the upmost quality and purity. Their facilities will be state-of-the-art utilizing multi-state proven methods to produce the highest of quality medical cannabis. Emerald Med Farms management and key personnel have a successful track record including a Master Grower with over 27 years of experience in California with both inside and outside growing for all styles of plant and vegetation. The company has also built a strong network of industry professionals ranging from research facilities to individual scientist from around the globe to support their endeavors. The Company operations are in full compliance to the medical marijuana California Co-Operative. The Co-Op maintains a roster of registered patients under “right to grow” which defines the number of plants per patient per script.
Emerald Med Farms has a marijuana crop in the process of maturing that is expected to be ready within the next 30 to 45 days for harvesting. The current crop is estimated to yield between 3 and 4 pounds per plant and, upon the successful harvesting of these strains of marijuana, the product will be distributed through a Cooperative of California medical dispensaries.
The marijuana plants are from two strains: 1) The OG Kush Strain which was originally from Northern California and has quickly become known around the world for its distinct aroma and strong effects. The OG Kush strain is one of the most popular medical marijuana strains grown and sold by dispensaries today. 2) Sour Diesel Strain which is named after its pungent, diesel-like aroma. This fast-acting strain delivers energizing, dreamy cerebral effects that provides stress, pain, and depression relief and provides long-lasting relief making it a top choice among medical patients.
The company has approved a 40% reduction in its authorized shares. The Company will reduce the number of authorized common shares from 1,000,000,000 to 600,000,000. Additionally, the Series A preferred shares shall no longer have conversion rights to common shares. QED is working with its registered agent, Corporate Creations, to file an amendment to the Articles of Incorporation with the Secretary of the State of New York and will be reflected in subsequent filings.
QEDN has completed its filings for year end 2013 and the first quarter 2014 to be in full compliance with its disclosures and financials as required by the OTC Markets guidelines. QED’s status on OTC Markets is now listed as OTC Pink Current Information.
The information contained herein is not intended to be investment advice and does not constitute any form of invitation or inducement by Mark Bonacci, analyst, to engage in investment activity. Neither the information nor any opinion expressed constitutes a solicitation for the purchase or sale of any security. Securities, financial instruments, strategies, or commentary mentioned herein may not be suitable for all investors and this material is not intended for any specific investor and does not take into account an investor’s particular investment objectives, financial situations or needs. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only current as of the stated date of their issue. Prices, values, or income from any securities or investments mentioned in this report may fluctuate, and an investor may, upon selling an investment lose a portion of, or the entire principal amount invested. Past performance is no guarantee of future results. Before acting on any recommendation in this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice.
This report may contain certain forward-looking statements and information, as defined within the meaning of section 27a of the securities act of 1933 and section 21e of the securities exchange act of 1934, and is subject to the safe harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Mark Bonacci, analyst. An outsourced research services provider represented by Mark Bonacci, analyst, provided Small Cap Specialists, LLC this article or report. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. Small Cap Specialists, LLC is not entitled to veto, interfere or alter the articles, documents or report once created and reviewed by the outsourced research provider represented by Mark Bonacci, analyst.
No warranty or liability assumed
GRCU, MDNT, GRDO, and QEDN have not compensated Small Cap Specialists, LLC or Mark Bonacci, analyst for the creation or dissemination of this report. Small Cap Specialists, LLC is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. Small Cap Specialists, LLC does not hold any positions in GRCU, MDNT, GRDO, and QEDN. No liability is accepted by Small Cap Specialists, LLC whatsoever for any direct, indirect or consequential loss arising from the use of this document. Small Cap Specialists, LLC expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Small Cap Specialists, LLC does not (1) guarantee the accuracy, timeliness, and completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
Small Cap Specialists, LLC is the party responsible for hosting the full analyst report and issuing the press release. Mark Bonacci, analyst, is the author of research report. Small Cap Specialists, LLC has compensated Mark Bonacci, analyst two hundred dollars for the right to disseminate this report. Information in this release is fact checked and produced on a best efforts basis by Mark Bonacci, analyst.